Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol
2. 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2h-pyran-3,4,5-triol
3. Bms 512148
4. Bms-512148
5. Bms512148
6. Dapagliflozin
7. Farxiga
8. Forxiga
1. 960404-48-2
2. Dapagliflozin Propanediol Monohydrate
3. Dapagliflozin Propanediol Hydrate
4. Farxiga
5. Dapagliflozin ((2s)-1,2-propanediol, Hydrate)
6. Bms-512148-05
7. Dapagliflozin S-propylene Glycol Monohydrate
8. Dapagliflozin Propylene Glycolate Hydrate
9. Chebi:85079
10. Dapagliflozin Propanediol [usan]
11. Dapagliflozin Mixture With Propylene Glycol, Hydrate
12. 887k2391vh
13. (2s,3r,4r,5s,6r)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol;(2s)-propane-1,2-diol;hydrate
14. Dapagliflozin [usan:inn]
15. Dapagliflozin Propylene Glycol Hydrate
16. (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol Compound With (s)-propane-1,2-diol (1:1) Hydrate
17. D-glucitol, 1,5-anhydro-1-c-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-, (1s)-, Compd. With (2s)-1,2-propanediol, Hydrate (1:1:1)
18. Unii-887k2391vh
19. Dapagliflozin Propylene Glycolate Hydrate [jan]
20. Dapagliflozin (s)-propylene Glycol Hydrate
21. Chembl2103802
22. Dtxsid00914678
23. Ex-a2824
24. Dapagliflozin Propylene Glycol
25. Hy-10450a
26. Mfcd28167768
27. S5566
28. Akos027250601
29. Ccg-269711
30. Ac-29230
31. As-64915
32. Dapagliflozin (2s)-1,2-propanediol Hydrate
33. F20667
34. Bms-512148 (2s)-1,2-propanediol, Hydrate
35. Dapagliflozin (2s)-1,2-propanediol Monohydrate
36. Xigduo Component Dapagliflozin Propanediol
37. A900162
38. Dapagliflozin Propanediol Component Of Xigduo
39. Dapagliflozin Propanediol Monohydrate [who-dd]
40. Q27158320
41. Dapagliflozin Propanediol Monohydrate [ema Epar]
42. Dapagliflozin Compound With (2s)-1,2-propanediol Hydrate
43. Dapagliflozin Compound With (2s)-1,2-propanediol Hydrate [mi]
44. (2s)-propane-1,2-diol (2s,3r,4r,5s,6r)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(hydroxymethyl)oxane-3,4,5-triol Hydrate
45. (2s)-propane-1,2-diol--(1s)-1,5-anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-d-glucitol--water (1/1/1)
46. (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro- 2h-pyran-3,4,5-triol, (2s)-propane-1,2-diol (1:1) Monohydrate
47. (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol (s)-propane-1,2-diol Hydrate
48. (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol, (2s)-propane-1,2-diol (1:1) Monohydrate
49. 1700615-13-9
Molecular Weight | 503.0 g/mol |
---|---|
Molecular Formula | C24H35ClO9 |
Hydrogen Bond Donor Count | 7 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 7 |
Exact Mass | 502.1969604 g/mol |
Monoisotopic Mass | 502.1969604 g/mol |
Topological Polar Surface Area | 141 Ų |
Heavy Atom Count | 34 |
Formal Charge | 0 |
Complexity | 493 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 6 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
Forxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance.
- in addition to other medicinal products for the treatment of type 2 diabetes.
For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied.
Heart failure
- Forxiga is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.
Chronic kidney disease
- Forxiga is indicated in adults for the treatment of chronic kidney disease.
Type 2 diabetes mellitus
Edistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance.
- in addition to other medicinal products for the treatment of type 2 diabetes.
For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 and 5. 1.
Heart failure
Edistride is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.
Chronic kidney disease
Edistride is indicated in adults for the treatment of chronic kidney disease.
Sodium-Glucose Transporter 2 Inhibitors
Compounds that inhibit SODIUM-GLUCOSE TRANSPORTER 2. They lower blood sugar by preventing the reabsorption of glucose by the kidney and are used in the treatment of TYPE 2 DIABETES MELLITUS. (See all compounds classified as Sodium-Glucose Transporter 2 Inhibitors.)
A10BK01
A10BK01
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Market Place
ANALYTICAL
ABOUT THIS PAGE
42
PharmaCompass offers a list of Dapagliflozin Propanediol Monohydrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Dapagliflozin Propanediol Monohydrate manufacturer or Dapagliflozin Propanediol Monohydrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Dapagliflozin Propanediol Monohydrate manufacturer or Dapagliflozin Propanediol Monohydrate supplier.
PharmaCompass also assists you with knowing the Dapagliflozin Propanediol Monohydrate API Price utilized in the formulation of products. Dapagliflozin Propanediol Monohydrate API Price is not always fixed or binding as the Dapagliflozin Propanediol Monohydrate Price is obtained through a variety of data sources. The Dapagliflozin Propanediol Monohydrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Dapagliflozin propylene glycolate hydrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dapagliflozin propylene glycolate hydrate, including repackagers and relabelers. The FDA regulates Dapagliflozin propylene glycolate hydrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dapagliflozin propylene glycolate hydrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Dapagliflozin propylene glycolate hydrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Dapagliflozin propylene glycolate hydrate supplier is an individual or a company that provides Dapagliflozin propylene glycolate hydrate active pharmaceutical ingredient (API) or Dapagliflozin propylene glycolate hydrate finished formulations upon request. The Dapagliflozin propylene glycolate hydrate suppliers may include Dapagliflozin propylene glycolate hydrate API manufacturers, exporters, distributors and traders.
click here to find a list of Dapagliflozin propylene glycolate hydrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Dapagliflozin propylene glycolate hydrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Dapagliflozin propylene glycolate hydrate active pharmaceutical ingredient (API) in detail. Different forms of Dapagliflozin propylene glycolate hydrate DMFs exist exist since differing nations have different regulations, such as Dapagliflozin propylene glycolate hydrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Dapagliflozin propylene glycolate hydrate DMF submitted to regulatory agencies in the US is known as a USDMF. Dapagliflozin propylene glycolate hydrate USDMF includes data on Dapagliflozin propylene glycolate hydrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Dapagliflozin propylene glycolate hydrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Dapagliflozin propylene glycolate hydrate suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Dapagliflozin propylene glycolate hydrate Drug Master File in Korea (Dapagliflozin propylene glycolate hydrate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Dapagliflozin propylene glycolate hydrate. The MFDS reviews the Dapagliflozin propylene glycolate hydrate KDMF as part of the drug registration process and uses the information provided in the Dapagliflozin propylene glycolate hydrate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Dapagliflozin propylene glycolate hydrate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Dapagliflozin propylene glycolate hydrate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Dapagliflozin propylene glycolate hydrate suppliers with KDMF on PharmaCompass.
A Dapagliflozin propylene glycolate hydrate written confirmation (Dapagliflozin propylene glycolate hydrate WC) is an official document issued by a regulatory agency to a Dapagliflozin propylene glycolate hydrate manufacturer, verifying that the manufacturing facility of a Dapagliflozin propylene glycolate hydrate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Dapagliflozin propylene glycolate hydrate APIs or Dapagliflozin propylene glycolate hydrate finished pharmaceutical products to another nation, regulatory agencies frequently require a Dapagliflozin propylene glycolate hydrate WC (written confirmation) as part of the regulatory process.
click here to find a list of Dapagliflozin propylene glycolate hydrate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Dapagliflozin propylene glycolate hydrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Dapagliflozin propylene glycolate hydrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Dapagliflozin propylene glycolate hydrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Dapagliflozin propylene glycolate hydrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Dapagliflozin propylene glycolate hydrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Dapagliflozin propylene glycolate hydrate suppliers with NDC on PharmaCompass.
Dapagliflozin propylene glycolate hydrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Dapagliflozin propylene glycolate hydrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Dapagliflozin propylene glycolate hydrate GMP manufacturer or Dapagliflozin propylene glycolate hydrate GMP API supplier for your needs.
A Dapagliflozin propylene glycolate hydrate CoA (Certificate of Analysis) is a formal document that attests to Dapagliflozin propylene glycolate hydrate's compliance with Dapagliflozin propylene glycolate hydrate specifications and serves as a tool for batch-level quality control.
Dapagliflozin propylene glycolate hydrate CoA mostly includes findings from lab analyses of a specific batch. For each Dapagliflozin propylene glycolate hydrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Dapagliflozin propylene glycolate hydrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Dapagliflozin propylene glycolate hydrate EP), Dapagliflozin propylene glycolate hydrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dapagliflozin propylene glycolate hydrate USP).